The rapid growth in diagnosed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to national directives for hospital emergency preparedness. Sheba Medical Center, a government hospital in Israel, undertook emergency measures to expand the inpatient quarantine capacity and converted two general medical wards to isolation wards with enhanced ventilation support capabilities.

Diabetes is associated with increased severity, complications, and mortality from coronavirus disease 2019 (COVID-19) ([@B1]). The care of patients with diabetes under strict isolation poses significant competing challenges of maintaining adequate quality of care achieved by multiple daily glucose measurements while minimizing risk of staff exposure, highlighting timely blood glucose management for the COVID-19 outbreak as an urgent need ([@B2]). To prevent patient-staff transmission while maintaining standard of care for hospitalized patients with diabetes, a way to monitor glucose levels remotely---from outside the designated isolated rooms---is required.

We report our experience in activating five monitoring stations per department based on personal continuous glucose monitoring (CGM) systems. We used CGM transmitters (Guardian Connect, MMT-7820ME; Medtronic) connected to glucose sensors (Enlite, MMT-7020; Medtronic) transmitting glucose values every 5 min through Bluetooth connectivity to designated mobile devices that upload data to the web through a Guardian Connect application. Real-time glucose monitoring in the control, viral-free area was viewed continuously by the team using CareLink personal websites. To allow data visualization of several patients on one control screen, the CareLink personal websites were accessed via different browsers and minimized to allow a view of real-time continuous glucose levels of up to four patients on a single screen. Training for physicians and nurses was provided by trained staff from the hospital's Division of Endocrinology, Diabetes and Metabolism. Teams were also provided with educational material and designated short videos for weekly replacement of sensors and instructions for timely calibrations. Calibrations were performed twice daily.

The request for remote glucose monitoring was made by the hospital on 18 March, and all monitoring stations were fully operational the following day. The first subjects who completed a week of remote glucose monitoring were one patient with type 1 diabetes on continuous subcutaneous insulin infusion and three patients with type 2 diabetes on a basal-bolus insulin regimen. Mean ± SD daily glucose measurements decreased from 3.75 ± 0.86 to 1.94 ± 0.31 with remote CGM (*P* = 0.005), with significant improvement in mean glucose levels from 258.2 ± 25.3 to 169.3 ± 7.9 mg/dL, respectively, *P* = 0.0006. Patient characteristics and glucose management parameters are detailed in [Table 1](#T1){ref-type="table"}. The main challenges included training alternating teams with the calibration procedure and cost. The analysis and report of the data were approved by the Institutional Review Board of Sheba Medical Center.

###### 

Characteristics of patients with COVID-19 and diabetes remotely managed with CGM

                                                 Patient 1   Patient 2           Patient 3                         Patient 4
  ---------------------------------------------- ----------- ------------------- --------------------------------- ----------------------------------------------------------------------------
  Age (years)                                    26          63                  76                                82
  Sex                                            F           F                   M                                 M
  Diabetes type                                  Type 1      Type 2              Newly diagnosed type 2            Type 2
  COVID-19 severity                              Mild        Moderate            Severe                            Severe
  Need for oxygen support                        Room air    Oxygen 4 L/min      Ventilator                        High-flow oxygen
  Additional comorbidities                       None        Ischemic CVA, HTN   HTN, NAFLD, CKD, hypothyroidism   HTN and dyslipidemia status post mechanical AVR, osteoporosis, past smoker
  Diabetes treatment                             CSII        MDI                 MDI                               MDI
  Glucose management before CGM                                                                                    
   Mean blood glucose tests per day              4.7         2.8                 3.75                              3.0
   Mean ± SD blood glucose (mg/dL)               127 ± 33    382 ± 188           192 ± 79                          183 ± 14
  Glucose management with remote real-time CGM                                                                     
   Mean blood glucose tests per day              2.3         1.5                 1.8                               2.1
   Mean ± SD blood glucose (mg/dL)               127 ± 32    200 ± 54            168 ± 63                          145 ± 45
   Time with transmitted data (%)                96.3        72.3                90.8                              97.2
   TIR \>250 mg/dL (%)                           0.0         13.2                13.7                              1.7
   TIR 180--250 mg/dL (%)                        5.7         56.7                29.0                              14.2
   TIR 110--180 mg/dL (%)                        60.4        30.0                32.7                              64.2
   TIR 70--110 mg/dL (%)                         33.1        0.1                 23.9                              12.6
   TIR \<70 mg/dL (%)                            0.8         0.0                 0.7                               5.6
   TIR \<54 mg/dL (%)                            0.0         0.0                 0.0                               1.7

AVR, aortic valve replacement; CSII, continuous subcutaneous insulin infusion; CVA, cerebrovascular accident; HTN, hypertension; MDI, multiple daily injections of insulin; NAFLD, nonalcoholic fatty liver disease; TIR, time in range.

In summary, converting a personal CGM system originally designed for diabetes self-management to team-based, real-time remote glucose monitoring offers a novel tool for inpatient diabetes control in COVID-19 isolation facilities. Such a solution in addition to ongoing remotely monitored clinical parameters (such as pulse rate, electrocardiogram, and oxygen saturation) adds to quality of diabetes care while minimizing risk of staff exposure and burden.

This article is part of a special article collection available at <https://care.diabetesjournals.org/collection/diabetes-and-COVID19>.
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